Author/Authors :
Gautschi، نويسنده , , O. and Huegli، نويسنده , , B. and Ziegler، نويسنده , , A. and Gugger، نويسنده , , M. and Heighway، نويسنده , , J. and Ratschiller، نويسنده , , Mark D. and Mack، نويسنده , , P.C. and Gumerlock، نويسنده , , P.H. and Kung، نويسنده , , H.J. and Stahel، نويسنده , , R.A. and Gandara، نويسنده , , D.R. and Betticher، نويسنده , , D.C.، نويسنده ,
Abstract :
Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP–PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.
Keywords :
Circulating DNA , lung cancer , Mutation , KRAS
